# RedDress Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reddress-medical

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.reddressmedical.com
- Total disclosed funding: $26M
- Latest round: Series D (May 24, 2023)
- Investors on record: 3

## About

Based in Florida, US, and founded in 2009 by its CEO, Alon Kushnir, and co-founder, Igal Kushnir, RedDress Medical Ltd. operates as a wound management company that specializes in creating personalized solutions for wound healing, leveraging the patient's blood to support the natural healing process. In May 2023, RedDress raised USD 25 million in series D funding from ATHOS Biopharma GmbH, HCS Capital Partners, and Ragnar Crossover Fund. As of April 2023, the company's wound care systems are available in 40 countries across five continents, including Brazil, Canada, Hong Kong, India, Mexico, Turkey, the United Arab Emirates, South Africa, Ireland, and Italy.

RedDress Medical Ltd.'s flagship product is the ActiGraft System, which enables healthcare providers to produce a topically applied blood clot from a patient's whole blood. The product can be used for a wide range of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other difficult-to-heal wounds. Additionally, the company offers the ActiGraft+ System, a wound management system that shortens the coagulation time and produces a higher-quality topically applied blood clot.

The company plans to use the series D funding to increase the adoption of its product, establish global partnerships, and expand its proprietary blood-based technology to treat more conditions.

## Funding rounds

- Series D, May 24, 2023, $26M — HCS Capital Partners, Ragnar Crossover Fund, ATHOS Biopharma GmbH

## Investors

- HCS Capital Partners (https://capitalatlas.ai/funds/hcs-capital-partners) — Series D
- Ragnar Crossover Fund (https://capitalatlas.ai/funds/ragnar-crossover-fund) — Series D
- ATHOS Biopharma GmbH — Series D